Overview

Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2018-10-24
Target enrollment:
Participant gender:
Summary
Primary objective • To evaluate the effect of rapid inhalation of 2.5μgiloprost using the Breelib nebulizer on pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension Secondary objectives - To evaluate the effect of rapid iloprost inhalation using the Breelib nebulizer on mean pulmonary arterial pressure (mPAP), cardiac output (CO), cardiac index (CI), systemic blood pressure, arterial oxygen saturation, heart rate, and pulmonary arterial wedge pressure (PAWP). - To evaluate the safety and tolerability of the rapid iloprost inhalation using the Breelib nebulizer.
Phase:
N/A
Details
Lead Sponsor:
University of Giessen
Treatments:
Iloprost